Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29675038 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL11660 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL6355287 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL8068410 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2030708 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL151048 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL3390891 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL9306687 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL20942976 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL2554264 | 0.95 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191338-A | Chemiluminescent immunoassay kit for detecting heat shock protein 70 and preparation method and application thereof | 山东省公共卫生临床中心 | 2024-06-14 | — | — | CN | claimed |
| CN-114181210-B | Preparation method of tetrahydrofolic acid | 深圳奥萨制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-114397449-A | Sample diluent for ELISA detection of avian leukosis virus antigen in meconium | 中科国创(南平)生物科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| US-8138255-B2 | Heat-resistant aluminum hydroxide and method for preparation thereof | KAWAI-LIME IND. CO. LTD. (JP) | 2012-03-20 | — | — | US | claimed |
| EP-2124899-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | Actavis Group hf. (IS) | 2009-12-02 | — | — | EP | claimed |
| WO-2008078341-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | ACTAVIS GROUP HF. (IS) | 2008-07-03 | — | — | WO | claimed |
| CN-114478795-B | Fusion protein for improving stability of oral administration of polypeptide drugs and application thereof | 安徽新熙盟生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117322529-A | Application of lactobacillus rhamnosus in preparation of hybrid pennisetum silage | 甘孜藏族自治州农业科学研究所 | 2024-01-02 | — | — | CN | disclosed |
| CN-115025280-B | Bacterial hydrolase response type hydrogel antibacterial dressing and preparation method thereof | 中山大学附属第七医院(深圳) | 2023-09-26 | — | — | CN | disclosed |
| CN-111057725-B | Use of ketoreductase for preparing (S) -1, 1-di (4-fluorophenyl) -2-propanol and preparation method thereof | 弈柯莱生物科技(上海)股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116555239-A | Immobilized sucrose isomerase fused with tag and production and application thereof | 大连工业大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-114395543-B | Trehalose synthase mutant and application thereof | 山东恒仁工贸有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-2124899-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | Actavis Group hf. (IS) | 2009-12-02 | — | — | EP | disclosed |
| EP-2117516-A2 | STABLE ATORVASTATIN FORMULATIONS | Actavis Group PTC EHF (IS) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008096377-A2 | STABLE ATORVASTATIN FORMULATIONS | ACTAVIS GROUP PTC EHF (IS) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008078341-A2 | STABLE PHARMACEUTICAL FORMULATIONS OF ATORVASTATIN MAGNESIUM SALT | ACTAVIS GROUP HF. (IS) | 2008-07-03 | — | — | WO | disclosed |
| US-20070160567-A1 | Allergen suppressor, allergen-suppression processed fiber and method of producing the same | SEKISUI CHEMICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20060216226-A1 | Heat-resistant aluminum hydroxide and method for preparation thereof | KAWAI-LIME IND. CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1703014-A1 | ALLERGEN SUPPRESSOR, ALLERGEN-SUPPRESSION PROCESSED FIBER AND METHOD OF PRODUCING THE SAME | Sekisui Chemical Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160567-A1 | Allergen suppressor, allergen-suppression processed fiber and method of producing the same | CMA1, TSLP, IL5 | SLC34A1 4630/4885LMNA 2319/4885KDM4E 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.